MEREO BIOPHARMA GROUP PLC

Climate Impact & Sustainability Data (2021)

Total Carbon Emissions:15 tCO2e/year

Scope 2 Emissions:15 tCO2e/year

Renewable Energy Share:100%

Total Energy Consumption:68,626 KWH/year

Reduced energy consumption in 2021 due to "work from home" guidance and office refurbishment prioritizing energy-saving choices (insulating floors, motion-activated lighting, heating system changes). Committed to sourcing electricity from fully renewable sources and migrating to more energy-efficient IT storage solutions.

Promoting a culture of diversity and inclusion; 52 employees as of the date of this annual report; implemented a revised long-term incentive plan in April 2019 to incentivize and retain employees; maintains constructive dialogue with employees through town hall meetings and video conference calls; operates a Code of Business Conduct and Ethics and an Employee Handbook including details of the whistleblowing policy.

Introduced new policies and procedures to ensure business practices align with Nasdaq listing expectations; updated Terms of Reference for Board Committees; cancelled admission of ordinary shares to trading on the AIM market of London Stock Exchange in December 2020; updated corporate governance policies and procedures to reflect sole listing on Nasdaq Global Market; continued progress in refining internal financial processes and controls to support attestation under Section 404(a) of the Sarbanes-Oxley Act of 2002; involved Audit and Risk Committee throughout the process.

Limited operating history and no revenue from product sales; need for additional funding to complete development, licensing, acquisition, and commercialization; heavy dependence on the success of etigilimab, alvelestat, and setrusumab; potential impact of the COVID-19 pandemic on clinical trials, regulatory engagement, and clinical trial supplies; dependence on patient enrollment in clinical trials; potential for costly liability claims; impact of healthcare legislation; highly competitive industry; challenges in developing sales, marketing, and distribution capabilities or entering into business arrangements; dependence on third parties for clinical trials and manufacturing; reliance on patents and intellectual property rights; potential for third-party patent infringement claims; challenges in retaining and recruiting key personnel; failure to establish and maintain effective internal controls; potential failure of partners to satisfy their obligations.
Environmental liability inherent in current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials; increasingly stringent environmental, health and safety laws and regulations.

In-house quality team with a GxP compliant quality management system; quality audits of CROs and clinical trial sites; specialized data analytics to validate clinical trial data; experienced in-house team working with specialist manufacturers; engagement with regulators, HTA bodies, treating physicians, patient representative organizations, and European payers; constant monitoring of competitor development programs; experienced in-house team working with regulatory advisors; dialogue with decision-makers and rigorous study preparation and design; new policies and procedures following U.S. listing; updates to Board Committee Terms of Reference; performing security assessments, due diligence, and privacy and security reviews of vendors; requiring third-party providers to sign agreements; refining internal financial processes and controls; experienced Head of IP and external counsel for IP portfolio; detailed quarterly cash flow forecasts; in-house team manages control over external vendors and partners for clinical trials under GxP.

Partnering with suppliers to ensure long-term mutually beneficial relationships and respect for human rights.

Frameworks Used: 2019 UK Government Environmental Reporting Guidelines, GHG Protocol Corporate Accounting and Reporting Standard